Prognostic value of body mass index in Korean patients with castration-resistant prostate cancer

Korean Journal of Urology

Volumn 53, Issue 11, 2012, Pages 761-765

  Park, Jeong Min ^a   Nam, Jung Soo ^b   Na, Woong ^c   Oh, Jong Jin ^d   Lee, Sangchul ^b   Hong, Sung Kyu ^b   Byun, Seok Soo ^b   Lee, Sang Eun ^b  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c National Medical Center   (South Korea)

^d CHA University   (South Korea)

Author keywords

Cancer specific survival; Castration resistant prostate cancer; Obesity

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DEATH; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBESITY; PROSTATECTOMY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84869767093     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2012.53.11.761     Document Type: Article

References (25)

1. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011;35:561-6.
2. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-53.
3. Chi BH, Chang IH. Prostate cancer: recent trends in Korea. Urol Int 2010;85:88-93.
4. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-4.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
6. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984;120:244-50.
7. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1998;73:401-6.
8. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
9. Jee SH, Yun JE, Park EJ, Cho ER, Park IS, Sull JW, et al. Body mass index and cancer risk in Korean men and women. Int J Cancer 2008;123:1892-6.
10. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011;378:815-25.
11. Lopez-Jimenez F, Cortes-Bergoderi M. Update: systemic diseases and the cardiovascular system (i): obesity and the heart. Rev Esp Cardiol 2011;64:140-9.
12. Cosin Aguilar J, Hernandiz Martinez A, Masramon Morell X, Aristegui Urrestarazu R, Aguilar Llopis A, Zamorano Gomez JL, et al. Overweight and obesity in hypertensive Spanish patients. The CORONARIA study. Med Clin (Barc) 2007;129:641-5.
13. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008;37:663-84.
14. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 2008;72:1246-51.
15. Irani J, Lefebvre O, Murat F, Dahmani L, Dore B. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int 2003;91:482-4.
16. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-78.
17. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446-53.
18. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 2007;110: 1478-84.
19. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 2006;107:631-9.
20. Lee SE, Lee WK, Jeong MS, Abdullajanov M, Kim DS, Park HZ, et al. Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men? BJU Int 2011; 107:1250-5.
21. Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 2003;63:8542-8.
22. Freedland SJ, Aronson WJ. Obesity and prostate cancer. Urology 2005;65:433-9.
23. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metabolism 1995;44(10 Suppl 4):37-44.
24. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
25. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340:1158-66.